Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine.
A common challenge for physicians prescribing GLP-1s is whether to increase the dose of Trulicity or switch patients to Mounjaro when managing uncontrolled Type 2 diabetes, according to the American College of Physicians. The 40-week study — sponsored by Eli Lilly, the manufacturer of both drugs — aimed to address this question.
Researchers compared the safety and efficacy of gradually escalating Trulicity doses up to 4.5 milligrams with Mounjaro at 15 milligrams, the maximum approved doses.
After 40 weeks, 21.3% of patients taking Mounjaro and 2.4% of those taking Trulicity achieved a hemoglobin A1C value below 5.7%, the benchmark for normal glucose levels. Additionally, 58% of patients taking Mounjaro and 6.8% of those taking Trulicity lost at least 10% of their body weight.
Evanston, Ill.-based Endeavor Health led the study, which included nearly 40 sites across five countries.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.